Floatz logo

RHENIUM RE-188 P2045

Large Cell Neuroendocrine (NE) Tumors

University of Maryland, Baltimoreprotein_peptidePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Large Cell Neuroendocrine (NE) Tumors cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
DEXAMETHASONE
AbbVie
Phase 1/2CCC
[212pb]pb-mp0712
Molecular Partners AG
Phase 1/2CCC

View all 11 →

Same molecule, other indications

RHENIUM RE-188 P2045 is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →